Ó³»­´«Ã½

Collaboration between Ó³»­´«Ã½ and Bayer leads to new treatment for a hard-to-treat type of lung cancer.

Ó³»­´«Ã½ researchers Matthew Meyerson and Heidi Greulich describe how they and Bayer scientists developed the first FDA-approved cancer drug to come from a Ó³»­´«Ã½ scientific discovery.

Count Me In’s legacy of data and resources will usher in a new way of doing research on other diseases and continue to fuel cancer studies around the globe.

In vivo CRISPR screens identify genes that improve persistence and function of CAR-T cells in a model of cancer

By classifying acute leukemia samples based on methylation patterns, MARLIN reduces diagnosis time from days to hours.

Tamoxifen encourages uterine cell growth in mice without causing mutations; findings could change how some breast cancers are treated in the future

Test of circulating tumor cells offers less invasive option for multiple myeloma surveillance, staging, and biological study compared to bone marrow biopsies

Findings suggest that previously-approved precision medicines may benefit children with certain childhood brain tumors.

Large analysis of genes and proteins in lung adenocarcinoma points to possible new diagnostic and treatment approaches, and also reveals signatures of chemical exposures in patients who have never smoked.

Mutation-based score provides a personalized indicator of disease severity and progression risk, could help inform early intervention strategies